eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
1/2022
vol. 8
 
Share:
Send email
Share:
abstract:
Original paper

Evaluation of safety and efficacy of tenofovir disoproxil in hemodialysis and renal transplant patients monoinfected with hepatitis B virus based on real life data

Filiz Akyüz
1
,
Bilger Çavuş
1
,
Nihan Nizam
1
,
Suut Göktürk
1
,
Bülent Baran
1
,
Halil Yazıcı
1
,
Sami Evirgen
1
,
Ümit Akyüz
2
,
Tuba Öbekli
1
,
Çetin Karaca
1
,
Kadir Demir
1
,
Fatih Beşışık
1
,
Sabahattin Kaymakoğlu
1

  1. İstanbul Medical Faculty, İstanbul University, Turkey
  2. Fatih Sultan Mehmet Research and Training Hospital, Turkey
Clin Exp HEPATOL 2022; 8, 1: 7-13
DOI: https://doi.org/10.5114/ceh.2022.114153
Online publish date: 2022/03/23
View full text Get citation
 
PlumX metrics:
Introduction
There are limited data about the safety of tenofovir disoproxil fumarate (TDF) in chronic renal failure (CRF). In this study, we aimed to evaluate the safety and efficacy of TDF in renal transplant recipients and hemodialysis patients with chronic hepatitis B (CHB) during long-term follow-up.

Material and methods
CHB patients undergoing hemodialysis (group 1), renal transplant recipients (group 2) and patients with normal renal function were included in the study. All patients were treated with TDF for at least 6 months. The groups were compared with regards to safety and efficacy. HBV-DNA levels were studied using a Cobas-TaqMan 96 system.

Results
A total of 217 patients with CHB (group 1: 8 patients, group 2: 9 patients, group 3: 200 patients) were enrolled in this study. The frequency of clinical adverse effects was significantly higher in groups 1 and 2compared with group 3 (37.5% vs. 11.1% vs. 0.5%, respectively, p < 0.001). However, no patients discontinued the drug due to the adverse effects. Serum creatinine levels were similar at baseline and at the end of follow-up in groups 1 and 2 (6.5 ±1.8 mg/dl and 6.9 ±1.5 mg/dl; 1.3 ±0.2 and 1.4 ±0.4 mg/dl, respectively, p < 0.05). HBV-DNA negativity rates were comparable at the 12th month and at the end of follow-up (50-83% for group 1, 60-67% for group 2 and 70-75% for group 3, respectively, p > 0.05).

Conclusions
Clinical adverse effects of TDF were more common in patients with CRF in comparison with patients without CRF. However, the occurrence of adverse effects did not necessitate discontinuation of the drug. TDF was safe and effective for this group of patients.

keywords:

safety, tenofovir, renal transplantation, hemodialysis, chronic hepatitis B
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.